|Funding amount:||14.500.000 EUR|
|Funding Period:||2018 - 2023|
|Project leader:||Dr. Sally Ellis|
Global Antibiotic Research & Development Partnership (GARDP)
15 Chemin Louis-Dunant
1202 Genf, Schweiz
The GARDP neonatal sepsis programme aims to provide an evidence base for the use of antibiotics, both old and new, in neonates with serious bacterial infections (SBIs), as the currently available standard of care in many countries is increasingly becoming less effective due to antimicrobial resistance. One of the long-term goals is the clinical development of formulations that are especially adapted for use in neonates.